Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 18/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7530756 | 0.89 | FFAR1 (0.38) | FFAR1P2RY12 | |
| SCHEMBL7006209 | 0.86 | PPARG (0.40) | — | |
| SCHEMBL7558343 | 0.83 | FFAR1 (0.36) | FFAR1P2RY12 | |
| Arginine SCHEMBL7006206 | 0.82 | PPARG (0.46) | — | |
| SCHEMBL7560961 | 0.82 | P2RY12 (0.35) | FFAR1P2RY12 | |
| SCHEMBL7532107 | 0.80 | FFAR1 (0.48) | FFAR1 | |
| SCHEMBL7526763 | 0.80 | FFAR1 (0.48) | FFAR1 | |
| SCHEMBL7528211 | 0.80 | FFAR1 (0.48) | FFAR1 | |
| SCHEMBL7531956 | 0.80 | FFAR1 (0.48) | FFAR1 | |
| SCHEMBL7528527 | 0.80 | FFAR1 (0.48) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020169175-A1 | Pharmaceutically acceptable salts of heterocyclic compounds | DR. REDDY'S LABORATORIES LTD. | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169175-A1 | Pharmaceutically acceptable salts of heterocyclic compounds | CYP3A43, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2D6 | FFAR1 2774/4885KDM4E 4581/4885ALDH1A1 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.